Loading stock data…
IRON
$66.91+0.96 (+1.46%)
Market ClosedLast close May 1
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Disc Medicine, Inc. in the Healthcare sector is trading at $66.91. The stock is currently 33% below its 52-week high of $99.50, remaining 6.7% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why IRON maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$66.91
Potential Upside
5%
Whystock Fair Value$70.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$100.17+49.7%
Range$75.00 – $128.00
Fundamentals
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United S...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.87%
Volume
Today's trading volume
289,562
Recent News
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge
Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals
Event Overview and Immediate Context Disc Medicine (IRON) has drawn fresh attention after recent share price moves, with the stock up about 3% over the past day but showing a negative return over the past month and past 3 months. See our latest analysis for Disc Medicine. The latest 3.0% 1 day share price return and 2.8% 7 day share price return sit against weaker recent momentum, with the 30 day and 90 day share price returns both negative while the 1 year and 3 year total shareholder...
Biotech Stocks Rally on Departure of Polarizing FDA Official
Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division and blocked several rare-disease drugs from receiving accelerated approval. Prasad’s stance had weighed heavily on the stocks of companies developing the drugs. Now those stocks are rallying after FDA Commissioner Marty Makary said Friday in an interview that Prasad will be departing at the end of April.
What 3 recent FDA rejections reveal about shifts inside the agency
The FDA’s approval strategy has been difficult to pin down, but recent decisions provide clues for how some of the most volatile initiatives will play out.
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection
This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company is cutting its workforce.